Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Response to Immunotherapy in Patients with High-Risk Smoldering Myeloma

Blood (2021) 138 (Supplement 1): 330.

https://doi.org/10.1182/blood-2021-147623

Published: 2021

Journal Articles

Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma

Elizabeth K. O'Donnell, MD, Jacob P. Laubach, MD, Andrew J. Yee, MD, Robert Redd, Carol Ann Huff, MD, Frank Basile, MD, Philip M. Wade, MD, Claudia E. Paba-Prada, MD, Irene M. Ghobrial, MD, Robert L. Schlossman, MD, Jill N. Burke, NP, Cynthia C. Harrington, NP, Kathleen J. Lively, RN, Hannah Lyons, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Noopur S. Raje, MD

Blood (2019) 134 (Supplement_1): 3178.

https://doi.org/10.1182/blood-2019-128000

Published: 2019

Journal Articles

Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Paul G. Richardson, MD, Myo Htut, MD, Cristina Gasparetto, MD, Jeffrey A. Zonder, Thomas G. Martin, III, MD, Janice Chen, PhD, Christopher Brooks, PhD, Peter McDonald, Nicole Rupprecht, Halyna Wysowskyj, Dharminder Chauhan, PhD, Arghya Ray, PhD, Kenneth C. Anderson, MD, Claudia E. Paba-Prada, MD

Blood (2019) 134 (Supplement_1): 3145.

https://doi.org/10.1182/blood-2019-130410

Published: 2019

Journal Articles

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Chia-jen Liu, MD, Irene M. Ghobrial, MD, Mark Bustoros, MD, Kaitlen Reyes, NP, Kalvis Hornburg, BA, Ashraf Z. Badros, MD, James J. Vredenburgh, MD, Adam Boruchov, MD, Jeffrey V Matous, MD, Aaron Caola, BS, Bradley Rivotto, BS, Alexandra Savell, BS, Patrick Henrick, BS, Claudia E. Paba-Prada, MD, Robert L. Schlossman, MD, Jacob Laubach, MD, Jacalyn Rosenblatt, MD, Andrew J Yee, MD, Omar Nadeem, MD, Rodrigo O. Maegawa, MD, Andrzej Jakubowiak, MD PhD, Saad Z. Usmani, MD, Manisha Bhutani, MD, Joseph Cappuccio, BS, Brianna Berrios, BS, Kimberly Noonan, NP, Oksana Zavidij, PhD, Tarek H Mouhieddine, MD, Cody J Boehner, Carl-Jannes Neuse, Karma Ziad Salem, MD, Mairead Reidy, PhD, Jihye Park, PhD, Michael Agius, PhD, Mahshid Rahmat, PhD, Salomon Manier, MD PhD, Divaya Bhutani, MD, Jeffrey A Zonder, MD, Nikhil Munshi, MD, Daniel Auclair, PhD, Kenneth Anderson, MD, Paul Richardson

Blood (2018) 132 (Supplement 1): 154.

https://doi.org/10.1182/blood-2018-154

Published: 2018

Journal Articles

Results from Ongoing Phase 1/2 Trial of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Myo Htut, MD, Cristina Gasparetto, MD, Jeffrey Zonder, MD, Thomas G. Martin, III, MD, Emma C. Scott, MD, Janice Chen, PhD, Shay Shemesh, MA, Christopher L. Brooks, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Claudia E. Paba-Prada, MD

Blood (2016) 128 (22): 5696.

https://doi.org/10.1182/blood.V128.22.5696.5696

Published: 2016

Journal Articles

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood (2016) 128 (22): 976.

https://doi.org/10.1182/blood.V128.22.976.976

Published: 2016

Journal Articles

IgM Myeloma: A Multicenter Retrospective Study of 159 Patients

Blood (2016) 128 (22): 3276.

https://doi.org/10.1182/blood.V128.22.3276.3276

Published: 2016

Journal Articles

Alliance A061202. a Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Versus Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor Based Therapy: Phase I Results

Peter M. Voorhees, MD, Flora Mulkey, Hani Hassoun, MD, Claudia E. Paba-Prada, MD, Yvonne A. Efebera, MD MPH, Eva Hoke, Guadalupe Aquino, Destin Carlisle, Vera Suman, Paul G. Richardson, MD

Blood (2015) 126 (23): 375.

https://doi.org/10.1182/blood.V126.23.375.375

Published: 2015

Journal Articles

Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Blood (2015) 126 (23): 4256.

https://doi.org/10.1182/blood.V126.23.4256.4256

Published: 2015

Journal Articles

A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Elizabeth K. O'Donnell, MD, Jacob P. Laubach, MD, Andrew J. Yee, MD, Carol A. Huff, MD, Frank G. Basile, MD, Philip M. Wade, Jr., MD, Claudia E. Paba-Prada, MD, Irene M. Ghobrial, MD, Robert L. Schlossman, MD, Nicole R. Couture, BSN, RN, Lauren Doherty, Hannah Lyons, Caroline English, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Noopur S. Raje, MD

Blood (2015) 126 (23): 4217.

https://doi.org/10.1182/blood.V126.23.4217.4217

Published: 2015

Journal Articles

Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free Survival

Peter M. Voorhees, MD, Valeria Magarotto, MD, Pieter Sonneveld, MD PhD, Torben Plesner, MD, Ulf-Henrik Mellqvist, MD PhD, Claudia E. Paba-Prada, MD, Catriona Byrne, RN, Johan Harmenberg, MDPhD, Eva Nordstrom, MSc,MBA, Antonio Palumbo, MD, Paul Richardson, MD

Blood (2015) 126 (23): 3029.

https://doi.org/10.1182/blood.V126.23.3029.3029

Published: 2015

Journal Articles

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Jacob P. Laubach, MD, Kenneth H. Shain, MD PhD, Rachid Baz, MD, Erica N Boswell, BS, Patrick M Henrick, MPH, Abdel Kareem Azab, Bpharm, PhD, Courtney Hanlon, Stacey Chuma, BSN, Houry Leblebjian, PharmD, BCOP, Kimberly Noonan, RN, NP, AOCN, Megan H. MacNabb, BA, Diane Warren, Philippe Armand, MD PhD, Claudia E. Paba-Prada, MD, Nikhil C. Munshi, MD, Robert L Schlossman, MD, Kenneth C. Anderson, MD, Paul G. Richardson

Blood (2014) 124 (21): 5777.

https://doi.org/10.1182/blood.V124.21.5777.5777

Published: 2014

Journal Articles

Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia

Irene M. Ghobrial, MD, Robert Allyn Redd, MS, Jeffrey Matous, Philippe Armand, MD PhD, Erica N Boswell, BS, Stacey Chuma, BSN, Kimberly Noonan, RN, NP, AOCN, Megan H. MacNabb, BA, Ranjit Banwait, Courtney Hanlon, Houry Leblebjian, PharmD, BCOP, Diane Warren, Jorge J. Castillo, MD, Jacob P. Laubach, MD, Claudia E. Paba-Prada, MD, Kenneth C. Anderson, MD, Paul G. Richardson, Edie A. Weller, PhD, Steven P Treon, MD MA, PhD

Blood (2014) 124 (21): 3081.

https://doi.org/10.1182/blood.V124.21.3081.3081

Published: 2014

Journal Articles

Incidence and Clinical Features of Extramedullary Multiple Myeloma in Patients Who Underwent Stem Cell Transplantation

Matthew Weinstock, MD, Yosra Aljawai, MS, Irene M. Ghobrial, MD, Elizabeth A. Morgan, MD, Jacob P. Laubach, MD, Aldo M Roccaro, MD PhD, Cindy Varga, Muriel Gannon, RN, Claudia E. Paba-Prada, MD, Robert L Schlossman, MD, Nikhil Munshi, Kenneth C. Anderson, Paul G. Richardson, Constantine S. Mitsiades, MD PhD

Blood (2014) 124 (21): 5746.

https://doi.org/10.1182/blood.V124.21.5746.5746

Published: 2014

Journal Articles

Time to Development of Treatment-Emergent Extramedullary and Osseous Plasmacytomas in the Era of Novel Agents: An Analysis of Upfront Regimens in Newly Diagnosed MM Incorporating Lenalidomide and Bortezomib

Cindy Varga, Jacob P. Laubach, MD, Irene M. Ghobrial, MD, Matthew Weinstock, MD, Claudia E. Paba-Prada, MD, Robert L. Schlossman, MD, Nikhil Munshi, Wanling Xie, MS, Edie A. Weller, PhD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD PhD, Paul G. Richardson

Blood (2014) 124 (21): 3468.

https://doi.org/10.1182/blood.V124.21.3468.3468

Published: 2014

Journal Articles

A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Elizabeth O'Donnell, MD, Jacob P. Laubach, MD, Andrew J Yee, MD, Carol Ann Huff, MD, Frank Basile, MD, Philip M. Wade, MD, Claudia E. Paba-Prada, MD, Irene M. Ghobrial, MD, Robert L Schlossman, MD, Nicole Couture, RN, Lauren Doherty, Hannah Lyons, RN, Caroline English, Nikhil Munshi, Kenneth C. Anderson, Paul G. Richardson, MD, Noopur Raje, MD

Blood (2014) 124 (21): 3454.

https://doi.org/10.1182/blood.V124.21.3454.3454

Published: 2014

Journal Articles

Assessment Of Drug Toxicity In Patients With and Without Renal Impairment Receiving Lenalidomide At a Large Academic Institution

Houry Leblebjian, PharmD, BCOP, Wanling Xie, MS, Paul G. Richardson, MD, Irene M. Ghobrial, MD, Christy Harris, PharmD, BCPS, BCOP, Robert L Schlossman, MD, Claudia E. Paba-Prada, MD, Nikhil C. Munshi, MD, Sylvia Bartel, R.Ph., M.H.P., Kenneth C. Anderson, MD, Edie A. Weller, PhD, Jacob P. Laubach, MD

Blood (2013) 122 (21): 1977.

https://doi.org/10.1182/blood.V122.21.1977.1977

Published: 2013

Journal Articles

Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstrom’s Macroglobulinemia

Steven Peter Treon, MD, MA, PhD, Christina K Tripsas, MA, Kirsten Meid, MPH, Steven J Cropper, Patrick Mostyn, Diane Warren, Claudia E. Paba-Prada, MD, Christopher Patterson, Guang Yang, PhD, Zachary Hunter, Janet Kunsman, NP, Sandra Kanan, NP, Irene M. Ghobrial, MD

Blood (2013) 122 (21): 757.

https://doi.org/10.1182/blood.V122.21.757.757

Published: 2013

Journal Articles

A Prospective Multicenter Study Of The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom’s Macroglobulinemia

Steven Peter Treon, MD, MA, PhD, Christina K Tripsas, MA, Guang Yang, PhD, Yang Cao, MD, Lian Xu, Zachary Hunter, Steven J Cropper, Patrick Mostyn, Kirsten Meid, MPH, Diane Warren, Christopher Patterson, Gaurav Varma, MSPH, Jacob P. Laubach, MD, Claudia E. Paba-Prada, MD, Janet Kunsman, NP, Irene M. Ghobrial, MD, Sandra Kanan, NP, Ranjana H. Advani, MD, Maria Lia Palomba, MD

Blood (2013) 122 (21): 251.

https://doi.org/10.1182/blood.V122.21.251.251

Published: 2013

Journal Articles

Incidence of Peripheral Neuropathy in Waldenström Macroglobulinemia Patients At Diagnosis,

Claudia E. Paba-Prada, MD, Ranjit Banwait, MA, Steven Treon, MD, PhD, Irene M. Ghobrial, MD

Blood (2011) 118 (21): 3692.

https://doi.org/10.1182/blood.V118.21.3692.3692

Published: 2011

NARROW

Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Response to Immunotherapy in Patients with High-Risk Smoldering Myeloma

Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma

Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Results from Ongoing Phase 1/2 Trial of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

IgM Myeloma: A Multicenter Retrospective Study of 159 Patients

Alliance A061202. a Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Versus Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor Based Therapy: Phase I Results

Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free Survival

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia

Incidence and Clinical Features of Extramedullary Multiple Myeloma in Patients Who Underwent Stem Cell Transplantation

Time to Development of Treatment-Emergent Extramedullary and Osseous Plasmacytomas in the Era of Novel Agents: An Analysis of Upfront Regimens in Newly Diagnosed MM Incorporating Lenalidomide and Bortezomib

A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Assessment Of Drug Toxicity In Patients With and Without Renal Impairment Receiving Lenalidomide At a Large Academic Institution

Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstrom’s Macroglobulinemia

A Prospective Multicenter Study Of The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom’s Macroglobulinemia

Incidence of Peripheral Neuropathy in Waldenström Macroglobulinemia Patients At Diagnosis,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only